IDEXX Laboratories (IDXX) Stock Forecast & Price Target

$560.36 +13.18 (+2.41%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$561.00 +0.64 (+0.11%)

As of 10/16/2026 07:30 PM Eastern

Compare

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
5

Buy
7

Based on 12 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 5 have given a hold rating, and 7 have given a buy rating for IDXX.

Consensus Price Target

$744.09
32.79% Upside

According to the 12 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $744.09. The highest price target for IDXX is $830.00, while the lowest price target for IDXX is $670.00. The average price target represents a forecasted upside of 32.79% from the current price of $560.36.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Analyst Ratings Over Time

Type	Current Forecast 10/17/25 to 10/17/26	1 Month Ago 9/17/25 to 9/17/26	3 Months Ago 7/19/25 to 7/19/26	1 Year Ago 10/17/24 to 10/17/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$744.09	$747.00	$751.00	$656.50
Forecasted Upside	32.79% Upside	47.49% Upside	32.35% Upside	3.32% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEXX Laboratories Stock vs. The Competition

Type	IDEXX Laboratories	Healthcare Companies	Broader Market
Consensus Rating Score	2.58	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	32.79% Upside	1,213.35% Upside	18.01% Upside
News Sentiment Rating	Positive News See Recent IDXX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/16/2026	The Goldman Sachs Group 3 of 5 stars	Matt Dellatorre Not Rated	Initiated Coverage	Buy	$740.00	+35.24%
10/16/2026	JPMorgan Chase & Co. 3 of 5 stars	Chris Schott 4 of 5 stars	Lower Target	Overweight	$775.00 ➝ $750.00	+32.64%
10/12/2026	KeyCorp 2 of 5 stars	Steve Dechert Not Rated	Initiated Coverage	Sector Weight
10/8/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold (C) ➝ Hold (C+)
8/11/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Glen Santangelo Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$800.00 ➝ $710.00	+19.18%
8/5/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Daniel Grosslight Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$650.00 ➝ $670.00	+13.93%
8/5/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Andrea Alfonso Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$620.00 ➝ $670.00	+14.57%
3/31/2026	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Jonathan Block Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$775.00 ➝ $675.00	+21.61%
2/9/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	David Westenberg Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$775.00 ➝ $750.00	+16.35%
2/3/2026	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Mark Massaro Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$830.00 ➝ $800.00	+25.08%
Get the Latest News and Ratings for IDXX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.
11/4/2025	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Erin Wright Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$765.00 ➝ $805.00	+11.60%
11/4/2025	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Keith Devas Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$830.00	+14.81%
11/3/2025	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Daniel Clark Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$785.00	+8.58%
2/4/2025	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Ryskin Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$475.00 ➝ $535.00	+14.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:43 AM ET.

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 14, 2026. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

IDEXX Laboratories, Inc. recently demonstrated strong fundamental performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $4.27 against a consensus estimate of $3.94, which indicates the company is generating higher profits than the market anticipated.
The company has shown consistent revenue growth, with the most recent quarter seeing revenue increase by 9.7% on a year-over-year basis, suggesting that demand for its veterinary diagnostic products and services remains robust and is expanding.
IDEXX Laboratories, Inc. currently trades at a stock price of $529.01, which is significantly below the average analyst price target of $747.00, implying that the stock may be undervalued relative to the long-term growth potential projected by financial experts.
The company maintains a strong financial position with a low debt-to-equity ratio of 0.19, meaning it relies less on borrowed money to fund its operations, which provides a safety cushion against economic downturns and allows for greater financial flexibility.
IDEXX Laboratories, Inc. has a high return on equity of 71.96%, a metric that measures how effectively the company uses shareholder capital to generate profits, indicating that management is highly efficient at turning invested money into earnings.

IDEXX Laboratories
Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

The stock is trading at a price-to-earnings ratio of 37.20, which is considered elevated, meaning investors are paying a premium for each dollar of earnings, and this high valuation leaves little room for error if future growth slows down.
Recent insider activity has been predominantly negative, with multiple executives and directors, including the CEO and EVPs, selling significant blocks of shares in early 2026, which can signal a lack of confidence in the stock's near-term upside from those closest to the company.
IDEXX Laboratories, Inc. has a beta of 1.55, a measure of volatility that indicates the stock is 55% more volatile than the overall market, meaning it is likely to experience larger price swings in both directions compared to the broader economy.
The company's current stock price of $529.01 is well below its 52-week high of $769.98, suggesting that the stock has undergone a significant correction and may be facing headwinds or market skepticism that has not yet been resolved.
Some institutional investors, such as First Citizens Bank & Trust Co., have recently decreased their stakes in the company, which may indicate that large financial players are re-evaluating their exposure to the stock or seeking to reduce risk in their portfolios.

IDXX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $744.09, with a high forecast of $830.00 and a low forecast of $670.00.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.

According to analysts, IDEXX Laboratories's stock has a predicted upside of 32.79% based on their 12-month stock forecasts.

Over the previous 90 days, IDEXX Laboratories's stock had 2 upgrades and 1 downgrade by analysts.

IDEXX Laboratories has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., KeyCorp, The Goldman Sachs Group, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like IDEXX Laboratories more than other "healthcare" companies. The consensus rating for IDEXX Laboratories is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IDXX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With IDEXX Laboratories Recommendations

MarketBeat monitors more than a dozen sources for IDEXX Laboratories analyst ratings, with the most recent rating issued on 10/16/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Stock Forecast & Price Target